Tech Company Financing Transactions
Clover Biopharmaceuticals Funding Round
Clover Biopharmaceuticals secured a $230 million Series C funding round on 2/25/2021. Backers included GL Ventures, Temasek Holdings and Delos Capital.
Transaction Overview
Company Name
Announced On
2/25/2021
Transaction Type
Venture Equity
Amount
$230,000,000
Round
Series C
Investors
GL Ventures (Lead Investor)
Temasek Holdings (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the continued development and expansion of its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 1 Incubation Park Chengdu Hi-Tech Zone No. 1480 Nor B5-19
Chengdu Sichuan, 610041
China
Chengdu Sichuan, 610041
China
Phone
Website
Email Address
Overview
Founded by a team of world-class scientists returning to China, Clover Biopharmaceuticals is passionate about developing transformative biologic therapies for the millions of Chinese patients who currently do not have access to modern biological medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Liang
Chief Financial Officer
Phillip Lee
Chief Medical Officer
Philippe Bishop
Chief Medical Officer
Htay Han
Chief Scientific Officer
Peng Liang
Chief Technical Officer
David He
Executive Vice President
Min Dong
Vice President
Andrew Baker
Vice President
Ping Li
Vice President
Igor Smolenov
Vice President
Chris Wallace
VP - Bus. Development
Steven Gong
VP - Manufacturing
Andrew Chin
VP - Operations
Vincent Mwangi
VP - Product Management
Xiaobing Li
VP - Regulatory Affairs
Cindy Min
VP - Regulatory Affairs
Jian Ren
Browse more venture capital transactions:
Prev: 2/25/2021: OpsCruise venture capital transaction
Next: 2/25/2021: Saltmine venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs